Virpax Pharmaceuticals, a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for Epoladerm (diclofenac epolamine) spray. Epoladerm is being developed in partnership with MedPharm, a contract provider of topical and transdermal product design and formulation development services. Epoladerm is an investigati...